Adeno‐associated virus (AAV)-based gene therapy for glioblastoma

Adeno‐associated virus (AAV)-based gene therapy for glioblastoma

Abstract Glioblastoma (GBM) is the most common and malignant Grade IV primary craniocerebral tumor caused by glial cell carcinogenesis with an extremely poor median survival of 12–18 months. The current standard treatments for GBM, including surgical resection followed by chemotherapy and radiothera...

Full description

Bibliographic Details
Main Authors: Xin Xu, Wenli Chen, Wenjun Zhu, Jing Chen, Bin Ma, Jianxia Ding, Zaichuan Wang, Yifei Li, Yeming Wang, Xiaochun Zhang
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Cancer Cell International
Subjects:
AAV
Glioblastoma
Gene therapy
Systemic injection
Local injection
Intracerebroventricular injection
Online Access:https://doi.org/10.1186/s12935-021-01776-4

Internet

https://doi.org/10.1186/s12935-021-01776-4

Similar Items